{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:52:22Z","timestamp":1779900742107,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.phrs.2018.01.010","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T09:18:43Z","timestamp":1517390323000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pharmacological intervention in hypertension using beta-blockers: Real\u2010world evidence for long-term effectiveness"],"prefix":"10.1016","volume":"130","author":[{"given":"Meritxell","family":"Sabid\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.amjcard.2010.08.023","article-title":"Beta-blockers in hypertension","volume":"106","author":"Ram","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.01.010_bib0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1026180325278","article-title":"Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS)","volume":"17","author":"Czuriga","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"7","key":"10.1016\/j.phrs.2018.01.010_bib0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.01.010_bib0020","series-title":"Hypertension in Adults: Diagnosis and Management (Updated 2016)","author":"National Institute for Health and Clinical Excellence","year":"2011"},{"key":"10.1016\/j.phrs.2018.01.010_bib0025","series-title":"Hypertension: The Clinical Managment of Primary Hypertension in Adults (Updated 2016)","author":"National Clinical Guidance Centre","year":"2011"},{"key":"10.1016\/j.phrs.2018.01.010_bib0030","first-page":"CD002003","article-title":"Beta-blockers for hypertension","volume":"11","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2018.01.010_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2007.01.069","article-title":"Are we misunderstanding beta-blockers","volume":"120","author":"Cruickshank","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.01.010_bib0040","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"8693","key":"10.1016\/j.phrs.2018.01.010_bib0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2018.01.010_bib0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2710.2003.00477.x","article-title":"A comparison of the beta1-selectivity of three beta1-selective beta-blockers","volume":"28","author":"Nuttall","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2018.01.010_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000683","article-title":"Efficacy and tolerability of a beta-1 selective beta blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study","volume":"2","author":"Channaraya","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2018.01.010_bib0060","first-page":"CD007451","article-title":"Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension","volume":"3","author":"Wong","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2018.01.010_bib0065","first-page":"55","article-title":"The efficacy of bisoprolol in the treatment of hypertension","volume":"8","author":"Mengden","year":"1997","journal-title":"Rev. Contemp. Pharmacother."},{"key":"10.1016\/j.phrs.2018.01.010_bib0070","first-page":"1","article-title":"The current role of \u03b2-blockers in cardiovascular medicine","volume":"8","author":"Cruickshank","year":"1997","journal-title":"Rev. Contemp. Pharmacother."},{"issue":"7160","key":"10.1016\/j.phrs.2018.01.010_bib0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"7160","key":"10.1016\/j.phrs.2018.01.010_bib0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2018.01.010_bib0085","series-title":"The Modern Role of Beta-Blockers in Cardiovascular Medicine","author":"Cruickshank","year":"2011"},{"issue":"15","key":"10.1016\/j.phrs.2018.01.010_bib0090","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.01.010_bib0095","series-title":"A Global Brief on Hypertension","author":"World Health Organization","year":"2013"},{"issue":"2","key":"10.1016\/j.phrs.2018.01.010_bib0100","doi-asserted-by":"crossref","first-page":"e0148349","DOI":"10.1371\/journal.pone.0148349","article-title":"The impact of the choice of data source in record linkage studies estimating mortality in venous thromboembolism","volume":"11","author":"Gallagher","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2018.01.010_bib0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.phrs.2018.01.010_bib0110","series-title":"Direct Communication: EMISdata","author":"CPRD","year":"2017"},{"key":"10.1016\/j.phrs.2018.01.010_bib0115","series-title":"2011 Census: Population and Household Estimates for England and Wales","author":"Office for National Statistics","year":"2011"},{"issue":"9","key":"10.1016\/j.phrs.2018.01.010_bib0120","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/HJH.0000000000001382","article-title":"Exploring factors associated with patients\u2019 adherence to antihypertensive drugs among people with primary hypertension in the United Kingdom","volume":"35","author":"Kurdi","year":"2017","journal-title":"J. Hypertens."},{"issue":"572","key":"10.1016\/j.phrs.2018.01.010_bib0125","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3399\/bjgp10X483562","article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review","volume":"60","author":"Khan","year":"2010","journal-title":"Br. J. Gen. Pract."},{"issue":"1","key":"10.1016\/j.phrs.2018.01.010_bib0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2018.01.010_bib0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J. Clin. Epidemiol."},{"issue":"11","key":"10.1016\/j.phrs.2018.01.010_bib0140","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/heartjnl-2014-307043","article-title":"Heart rate is associated with progression of atrial fibrillation, independent of rhythm","volume":"101","author":"Holmqvist","year":"2015","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.phrs.2018.01.010_bib0145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9971","key":"10.1016\/j.phrs.2018.01.010_bib0150","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(14)61171-5","article-title":"Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials","volume":"385","author":"Blood Pressure Lowering Treatment Trialist\u015b Collaboration","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2018.01.010_bib0155","article-title":"Diabetes and the younger\/middle-aged hypertensive subject; obesity, sympathetic nerve activity and treatment implications","volume":"2","author":"Cruickshank","year":"2016","journal-title":"J. Diab. Res. Ther."},{"key":"10.1016\/j.phrs.2018.01.010_bib0160","series-title":"Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4","author":"Helfand","year":"2009"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181731575X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181731575X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T14:41:32Z","timestamp":1532356892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181731575X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"alternative-id":["S104366181731575X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.01.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological intervention in hypertension using beta-blockers: Real\u2010world evidence for long-term effectiveness","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}